Valuation
- Market cap
- 7,060,000
- Revenue TTM
- $0
- Net income TTM
- $-7,970,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 80,700
- Avg volume
- 133,818
- Day's range
- $1.25 – $1.30
- Shares out
- 5,559,000
- Stochastic %K
- 27%
- Beta
- -2.05
- Analysts
- Strong Sell
- Price target
- $17.00
Company profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parentera...
Show more
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 917 533 1469
- Website
- https://www.acurxpharma.com
- Address
- 259 Liberty Avenue, Staten Island, United States
Latest news
No headlines yet.
